https://www.nejm.org/doi/10.1056/NEJMoa2304748
In a trial, 661 patients with complicated UTI were randomized to receive cefepime–taniborbactam or meropenem. Of 436 in the microITT population, 70.6% on cefepime–taniborbactam vs. 58.0% on meropenem achieved composite success, showing superior efficacy (P=0.009). Safety profiles were similar.
